Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

127.86 -0.51 (-0.40%)
Streaming Delayed Price Updated: 11:25 AM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
A large peer is snapping up the company in a premium-priced deal. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Could this player be heading into a new era of growth? 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
From Merck & Co., Inc.
Via Business Wire
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
From Merck & Co., Inc.
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
Via MarketBeat
News headline image
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
From Merck & Co., Inc.
Via Business Wire
News headline image
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
From Merck & Co., Inc.
Via Business Wire
News headline image
1 Reason Eli Lilly Stock Is Still a Buy ↗
Eli Lilly is much more than just a weight loss stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
They could make important breakthroughs in their target markets. 
Via The Motley Fool
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
Via MarketMinute
Topics Intellectual Property
ARM Makes Its Move While Wall Street Watches the Strait ↗
Via Chartmill
News headline image
The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
From Merck & Co., Inc.
Via Business Wire
News headline image
1 S&P 500 Stock to Target This Week and 2 We Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗
They aren't just "pandemic stocks." 
Via The Motley Fool
Topics Intellectual Property
News headline image
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
From Merck & Co., Inc.
Via Business Wire
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,... 
Via MarketMinute
Topics Earnings Economy Initial Public Offering
News headline image
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
From Merck Sharp & Dohme
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.